Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing

We developed a strategy to combine conventional targeted therapy with immune checkpoint blockade using a tumor-targeting bispecific antibody (BsAb) to treat solid tumors. The BsAb was designed to simultaneously engage a tumor-associated antigen, epidermal growth factor receptor (EGFR), and programed...

Full description

Bibliographic Details
Main Authors: Li Li, Lan Deng, Xiaoqing Meng, Changling Gu, Li Meng, Kai Li, Xuesai Zhang, Yun Meng, Wei Xu, Le Zhao, Jianhe Chen, Zhenping Zhu, Haomin Huang
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Subjects:
Bispecific antibody
PD1
EGFR
Immune checkpoint blockade
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304083

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320304083

Similar Items